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ABSTRACT
Levonorgestrel-containing intrauterine contraceptive de-
vices, marketed as Mirena (Bayer HealthCare Pharmaceu-
ticals, Inc. Australia) are widely used in contemporary
gynecology, primarily as an effective method for contra-
ception and for control of menstrual disorders like men-
orrhagia and dysmenorrhea. In this article, the authors
report 2 cases of Mirena migration following intrauterine
insertion by general practitioners (family physicians). In
the first case, the contraceptive device had moved to the
patient’s right iliac fossa just anterior to the cecum and, in
the second, within the peritoneal cavity close to the left
leaf of the diaphragm. Both patients underwent unevent-
ful laparoscopic retrieval of the devices.
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SUMMARY OF CLINICAL FEATURES
Patient One
CM is a 44-year-old multiparous lady, with children 19 and
17 years of age. She delivered both of her children by
spontaneous vaginal deliveries. About 15 months ago, she
was fitted with a Mirena for contraception. Regular vaginal
examinations by her family physician confirmed that the
threads of Mirena were coming off the uterine cervix. She
was totally asymptomatic when she went for a periodic
cervical smear, at which point this problem with the Mirena
device was detected. Ultrasound scan confirmed that the
device was not present within the uterine cavity. A comput-
erized tomography scan showed that the device had at-
tached to the posterior aspect of the patient’s right rectus
sheath. Laparoscopy was performed by using the “triple
port” of entry, and the device was found in the patient’s right
iliac fossa just above her cecum and was surrounded by
omental adhesions. Laparoscopic adhesiolysis was affected
to free the device off the omental and cecal adhesions and
that was followed by laparoscopic retrieval of the Mirena
(Figures 1 and 2). The procedure was uneventful, and
there was no sign of uterine perforation. The patient was
discharged after the outpatient procedure.
Patient Two
NG is a 19-year-old single lady. She underwent an unre-
markable vaginal suction termination of her first preg-
nancy (STOP) at about 8 week’s gestation and was fitted
with a Mirena, at the same time, by the treating physician.
She was admitted to the hospital 10 days after the Mirena
insertion with a history of acute severe pelvic pain that
required administration of narcotic analgesic injections.
Ultrasound scanning showed that the uterus was “empty.”
Plain X-ray of the abdomen showed that the Mirena was in
the peritoneal cavity close to the pouch of Douglas. Emer-
gency laparoscopy (“triple port” of entry) was performed,
and the peritoneal cavity was carefully inspected. The
Mirena was spotted within approximately 3cm of the left
leaf of the diaphragm (Figures 3 and 4). There was no
sign of uterine perforation. Laparoscopic removal of the
device was carried out smoothly, and the patient was
discharged after the outpatient procedure.
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CASE REPORTDISCUSSION
The levonorgestrel-releasing intrauterine system (LNG-
IUS, Mirena) is the most widely used contraceptive
method, with prevalence rates ranging among countries
from 2% to 80% of contraceptive users.1 It releases
20gm of levonorgestrel/day2 and is used as an effec-
tive and reliable method of contraception, to manage
menstrual disorders as in menorrhagia3 and dysmenor-
rhoea,4 as an endometrial protective agent in women
using hormonal replacement therapy (HRT),5 and in the
management of select cases of endometrial carcinoma6
and precancerous conditions, such as atypical endome-
trial hyperplasia.7
As a contraceptive, Mirena is probably the most effective
reversible method of contraception8 and without the need
to take daily oral medication, as is the case with combined
oral contraceptive or progesterone-only pills.9 It is well
tolerated, long acting, reversible, and adequately retained
within the uterine cavity. Patient satisfaction is high with
acceptance among parous and nulliparous women alike,
as in the above 2 patients, and it also provides reassuring
results for clinicians and adolescents considering use of
Mirena.10
In addition, Mirena is usually recommended as a means of
contraception in “high risk” patients as in those with a
history of deep venous thrombosis,11 type 1 diabetes mel-
litus,12 liver disease,13 epileptic seizures,14 and immuno-
Figure 1. Migrated Mirena
® lying within abdominal cavity on
top of the cecum, surrounded by omental adhesions.
Figure 2. Laparoscopic retrieval of the migrated Mirena
® de-
vice, following an adhesiolysis procedure.
Figure 3. Migrated Mirena
® is close to the left leaf of the
patient’s diaphragm.
Figure 4. Laparoscopic retrieval of the migrated Mirena
® de-
vice.
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JSLS (2011)15:127–130 128compromised conditions including HIV.15 Nevertheless,
like many therapeutics in contemporary medicine, Mirena
has some side effects. Continuing pain and discomfort as
well as irregular vaginal bleeding are most likely the main
reasons for patients’ requests to discontinue the Mirena
device therapy.16 Discontinuation is accompanied by re-
turn of fertility.17 Contrary to old views, the device does
not increase the incidence of pelvic inflammatory dis-
ease18 and infertility, nor does it enhance tubal ectopic
pregnancies in women with no sexually transmitted infec-
tions.19 In fact, Mirena may be considered protective
against infection, especially in nulliparous women.20
Uterine perforation related to the insertion of this device is
one of the recognized side effects of Mirena. The inci-
dence of such perforations varies from 0 to 2.6 per 1000
insertions and is largely related to the experience of the
operating clinician.21,22 Expulsion of the device, however,
can happen in about 8 per 1000 insertions.23 In case
number 1 above, the uterine perforation was thought to
have happened more than a year after insertion, because
the patient had periodic speculum examinations initially
every month for the first 3 months, then followed by 1
speculum exam every 3 months for the subsequent year.
The “threads” of the Mirena device were clearly seen
coming off the cervix. The patient remained completely
asymptomatic until the device was laparoscopically re-
moved after the threads ceased to be visualized through
the cervix. Imaging, especially ultrasonography, has a
crucial role in the evaluation and management of intra-
uterine contraceptive devices and associated complica-
tions.24 Although it is difficult to be certain of the exact
cause of “migration” of intrauterine contraceptive devices
within the peritoneal cavity, a possible mechanism is that
the peristalsis of the intestines could well assist this jour-
ney within the patient’s abdomen after uterine perforation
has occurred.
In case number 2, the patient experienced severe, ex-
cruciating pelvic pain, a common symptom of uterine
perforation. Interestingly, there was no sign of perfora-
tion of the uterus on laparoscopic examination during
the Mirena procedure. In relation to the management
of this case, one may ask the question: Was it a good
idea to insert the intrauterine contraceptive device im-
mediately following STOP (Suction Termination of
Pregnancy)? In fact, there is no evidence to support the
idea that delayed insertion of the device carries fewer
complications.25 Immediate insertion after first- and
second-trimester abortions has a high initial continua-
tion and patient satisfaction rate.26 Moreover, this simul-
taneous therapeutic approach assures the operating cli-
nician and the patient that an unwanted pregnancy in
the future is very unlikely with the Mirena device in-
serted on the same occasion as the termination of preg-
nancy is to be carried out.27
CONCLUSION
Because Mirena is gaining in popularity among clinicians
and enjoys a wide range of candidacy among gynecolog-
ical patients, it is imperative that health care providers are
fully informed of the value as well as the possible side
effects of the device, notably uterine perforation. An ex-
perienced gynecological endoscopist should be able to
safely remove a missed Mirena out of the peritoneal cavity
without any complications.
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